Operaciones Gilead Sciences - GILD CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.29 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Gilead Sciences Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 77.23 |
| Abrir* | 76.84 |
| Cambio de 1 año* | 29.91% |
| Rango del día* | 76.49 - 77.61 |
| Rango de 52 semanas | 57.17-89.74 |
| Volumen medio (10 días) | 6.95M |
| Volumen medio (3 meses) | 127.72M |
| Capitalización de mercado | 96.41B |
| Ratio P/E | 21.25 |
| Acciones en circulación | 1.25B |
| Ingresos | 27.28B |
| EPS | 3.64 |
| Dividendo (Rendimiento %) | 3.88048 |
| Beta | 0.40 |
| Próxima fecha de resultados | Apr 26, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Mar 17, 2023 | 77.23 | -2.28 | -2.87% | 79.51 | 79.78 | 76.46 |
| Mar 16, 2023 | 78.98 | 0.19 | 0.24% | 78.79 | 79.88 | 77.74 |
| Mar 15, 2023 | 78.98 | -0.65 | -0.82% | 79.63 | 79.82 | 78.03 |
| Mar 14, 2023 | 78.62 | -0.12 | -0.15% | 78.74 | 79.83 | 78.24 |
| Mar 13, 2023 | 79.28 | -0.26 | -0.33% | 79.54 | 81.19 | 76.94 |
| Mar 10, 2023 | 79.00 | 0.48 | 0.61% | 78.52 | 80.24 | 77.61 |
| Mar 9, 2023 | 78.90 | -0.83 | -1.04% | 79.73 | 80.58 | 78.22 |
| Mar 8, 2023 | 79.73 | -0.36 | -0.45% | 80.09 | 80.68 | 79.48 |
| Mar 7, 2023 | 79.79 | -0.94 | -1.16% | 80.73 | 81.23 | 79.79 |
| Mar 6, 2023 | 81.04 | 0.27 | 0.33% | 80.77 | 81.25 | 80.35 |
| Mar 3, 2023 | 80.57 | 1.14 | 1.44% | 79.43 | 81.09 | 79.03 |
| Mar 2, 2023 | 79.43 | -0.05 | -0.06% | 79.48 | 79.83 | 78.44 |
| Mar 1, 2023 | 79.31 | -0.98 | -1.22% | 80.29 | 80.58 | 78.93 |
| Feb 28, 2023 | 79.96 | -0.55 | -0.68% | 80.51 | 80.92 | 79.28 |
| Feb 27, 2023 | 80.53 | 0.05 | 0.06% | 80.48 | 81.24 | 79.61 |
| Feb 24, 2023 | 80.59 | -1.69 | -2.05% | 82.28 | 82.49 | 80.13 |
| Feb 23, 2023 | 82.19 | -0.74 | -0.89% | 82.93 | 83.77 | 82.10 |
| Feb 22, 2023 | 82.93 | -1.75 | -2.07% | 84.68 | 84.83 | 82.93 |
| Feb 21, 2023 | 84.68 | 0.56 | 0.67% | 84.12 | 85.41 | 83.75 |
| Feb 17, 2023 | 84.35 | 1.17 | 1.41% | 83.18 | 85.18 | 81.65 |
Gilead Sciences Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos totales | 30390 | 26107 | 22127 | 22449 | 24689 | 27305 |
| Ingresos | 30390 | 26107 | 22127 | 22449 | 24689 | 27305 |
| Coste de los ingresos, total | 4261 | 4371 | 4853 | 4675 | 4572 | 6601 |
| Beneficio bruto | 26129 | 21736 | 17274 | 17774 | 20117 | 20704 |
| Gastos totales de explotación | 12757 | 11983 | 13927 | 18162 | 20618 | 17387 |
| Gastos de venta/general/administración Gastos, total | 3398 | 3830 | 4056 | 4381 | 5151 | 5246 |
| Investigación y desarrollo | 4266 | 3512 | 4846 | 8934 | 10895 | 5540 |
| Gastos (ingresos) extraordinarios | 832 | 270 | 172 | 172 | ||
| Ingresos de explotación | 17633 | 14124 | 8200 | 4287 | 4071 | 9918 |
| Ingresos por intereses (gastos), netos No operativos | -790 | -1190 | -964 | 227 | -2684 | -1611 |
| Otros, netos | 254 | 595 | 563 | 646 | 282 | -29 |
| Ingresos netos antes de impuestos | 17097 | 13529 | 7799 | 5160 | 1669 | 8278 |
| Ingresos netos después de impuestos | 13488 | 10136 | 5464 | 5364 | 89 | 6201 |
| Intereses menores | 13 | -16 | -5 | 22 | 34 | 24 |
| Beneficio neto antes de partidas extra. Elementos | 13501 | 10120 | 5459 | 5386 | 123 | 6225 |
| Ingresos netos | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 13501 | 10120 | 5459 | 5386 | 123 | 6225 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Ajuste por dilución | 0 | |||||
| Beneficio neto diluido | 13501 | 4628 | 5455 | 5386 | 123 | 6225 |
| Promedio ponderado de acciones diluidas | 1358 | 1319 | 1308 | 1277 | 1263 | 1262 |
| BPA diluido sin partidas extraordinarias | 9.94183 | 7.67248 | 4.17355 | 4.2177 | 0.09739 | 4.93265 |
| Dividends per Share - Common Stock Primary Issue | 1.84 | 2.08 | 2.28 | 2.52 | 2.72 | 2.84 |
| BPA normalizado diluido | 10.4252 | 7.82584 | 4.26568 | 4.30525 | 0.09739 | 4.93265 |
| Total de partidas extraordinarias | -5492 | -4 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 6423 | 6217 | 7421 | 7244 | 6590 |
| Ingresos | 6423 | 6217 | 7421 | 7244 | 6590 |
| Coste de los ingresos, total | 1361 | 1390 | 1223 | 2627 | 1424 |
| Beneficio bruto | 5062 | 4827 | 6198 | 4617 | 5166 |
| Gastos totales de explotación | 3533 | 3971 | 3579 | 6304 | 6393 |
| Gastos de venta/general/administración Gastos, total | 1044 | 1351 | 1190 | 1650 | 1083 |
| Investigación y desarrollo | 1117 | 1230 | 1166 | 2027 | 1186 |
| Gastos (ingresos) extraordinarios | 11 | 2700 | |||
| Ingresos de explotación | 2890 | 2246 | 3842 | 940 | 197 |
| Ingresos por intereses (gastos), netos No operativos | -608 | -430 | -392 | -181 | -334 |
| Otros, netos | -18 | 1 | -12 | -15 | |
| Ingresos netos antes de impuestos | 2264 | 1817 | 3438 | 759 | -152 |
| Ingresos netos después de impuestos | 1722 | 1517 | 2586 | 376 | 12 |
| Intereses menores | 7 | 5 | 6 | 6 | 7 |
| Beneficio neto antes de partidas extra. Elementos | 1729 | 1522 | 2592 | 382 | 19 |
| Ingresos netos | 1729 | 1522 | 2592 | 382 | 19 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 1729 | 1522 | 2592 | 382 | 19 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 1729 | 1522 | 2592 | 382 | 19 |
| Beneficio neto diluido | 1729 | 1522 | 2592 | 382 | 19 |
| Promedio ponderado de acciones diluidas | 1262 | 1260 | 1262 | 1262 | 1262 |
| BPA diluido sin partidas extraordinarias | 1.37005 | 1.20794 | 2.05388 | 0.30269 | 0.01506 |
| Dividends per Share - Common Stock Primary Issue | 0.71 | 0.71 | 0.71 | 0.71 | 0.73 |
| BPA normalizado diluido | 1.37668 | 1.20794 | 2.05388 | 0.30269 | 1.40571 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Activo Corriente | 19588 | 31823 | 35836 | 30296 | 15996 | 14772 |
| Efectivo e inversiones a corto plazo | 11895 | 25510 | 30089 | 24352 | 7408 | 6520 |
| Efectivo y Equivalentes | 8229 | 7588 | 17940 | 11631 | 5997 | 5338 |
| Inversiones a corto plazo | 3666 | 17922 | 12149 | 12721 | 1411 | 1182 |
| Total deudores, neto | 4514 | 3851 | 3327 | 3582 | 4892 | 4493 |
| Accounts Receivable - Trade, Net | 4514 | 3851 | 3327 | 3582 | 4892 | 4493 |
| Total Inventory | 1587 | 801 | 814 | 922 | 1683 | 1618 |
| Prepaid Expenses | 1592 | 1649 | 1533 | 1403 | 2013 | 2141 |
| Total Assets | 56977 | 70283 | 63675 | 61627 | 68407 | 67952 |
| Property/Plant/Equipment, Total - Net | 2865 | 3295 | 4006 | 5170 | 5613 | 5663 |
| Goodwill, Net | 1172 | 4159 | 4117 | 4117 | 8108 | 8332 |
| Intangibles, Net | 8971 | 17100 | 15738 | 13786 | 33126 | 33455 |
| Long Term Investments | 20495 | 11194 | 1423 | 1488 | 502 | 1309 |
| Other Long Term Assets, Total | 3886 | 2712 | 2555 | 6770 | 5062 | 4421 |
| Total Current Liabilities | 9218 | 11635 | 10605 | 9759 | 11397 | 11610 |
| Accounts Payable | 1206 | 814 | 790 | 713 | 844 | 705 |
| Accrued Expenses | 7775 | 7271 | 6876 | 6254 | 7198 | 7600 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 2747 | 2748 | 2499 | 2757 | 1516 |
| Other Current Liabilities, Total | 237 | 803 | 191 | 293 | 598 | 1789 |
| Total Liabilities | 38090 | 49841 | 42288 | 39102 | 50205 | 46883 |
| Total Long Term Debt | 26346 | 30795 | 24574 | 22094 | 28645 | 25179 |
| Long Term Debt | 26346 | 30795 | 24574 | 22094 | 28645 | 25179 |
| Minority Interest | 476 | 59 | 147 | 125 | 19 | -5 |
| Other Liabilities, Total | 2050 | 7352 | 6962 | 7124 | 10144 | 5743 |
| Total Equity | 18887 | 20442 | 21387 | 22525 | 18202 | 21069 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 454 | 1264 | 2282 | 3051 | 3880 | 4661 |
| Retained Earnings (Accumulated Deficit) | 18154 | 19012 | 19024 | 19388 | 14381 | 16324 |
| Unrealized Gain (Loss) | -16 | 194 | -52 | 1 | 2 | -4 |
| Other Equity, Total | 294 | -29 | 132 | 84 | -62 | 87 |
| Total Liabilities & Shareholders’ Equity | 56977 | 70283 | 63675 | 61627 | 68407 | 67952 |
| Total Common Shares Outstanding | 1307 | 1308 | 1282 | 1266 | 1254 | 1254 |
| Other Current Assets, Total | 12 | 73 | 37 | |||
| Property/Plant/Equipment, Total - Gross | 4289 | 5197 | 6592 | 7281 | 7556 | |
| Accumulated Depreciation, Total | -994 | -1191 | -1422 | -1668 | -1893 | |
| Deferred Income Tax | 4356 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 13278 | 13925 | 13991 | 14772 | 12629 |
| Efectivo e inversiones a corto plazo | 5666 | 6525 | 5738 | 6520 | 5325 |
| Efectivo y Equivalentes | 4065 | 4893 | 4362 | 5338 | 4296 |
| Inversiones a corto plazo | 1601 | 1632 | 1376 | 1182 | 1029 |
| Total deudores, neto | 3925 | 4149 | 4566 | 4493 | 3787 |
| Accounts Receivable - Trade, Net | 3925 | 4149 | 4566 | 4493 | 3787 |
| Total Inventory | 1779 | 1772 | 1676 | 1618 | 1482 |
| Prepaid Expenses | 1908 | 1479 | 2011 | 2141 | 2035 |
| Total Assets | 67492 | 67984 | 67098 | 67952 | 63080 |
| Property/Plant/Equipment, Total - Net | 4990 | 4996 | 5037 | 5121 | 5253 |
| Goodwill, Net | 8334 | 8334 | 8332 | 8332 | 8314 |
| Intangibles, Net | 34781 | 34341 | 33900 | 33455 | 30331 |
| Long Term Investments | 579 | 836 | 1099 | 1309 | 1427 |
| Other Long Term Assets, Total | 5530 | 5552 | 4739 | 4963 | 5126 |
| Total Current Liabilities | 9705 | 10214 | 10245 | 11610 | 8558 |
| Accounts Payable | 570 | 608 | 585 | 705 | 583 |
| Accrued Expenses | 6661 | 6906 | 6702 | 7600 | 6483 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 2259 | 2261 | 2511 | 1516 | 1025 |
| Other Current Liabilities, Total | 215 | 439 | 447 | 1789 | 467 |
| Total Liabilities | 48540 | 48281 | 45628 | 46883 | 43153 |
| Total Long Term Debt | 27907 | 27914 | 25175 | 25179 | 25183 |
| Long Term Debt | 27907 | 27914 | 25175 | 25179 | 25183 |
| Deferred Income Tax | 4464 | 4374 | 4603 | 4356 | 3687 |
| Minority Interest | 12 | 7 | 1 | -5 | -12 |
| Other Liabilities, Total | 6452 | 5772 | 5604 | 5743 | 5737 |
| Total Equity | 18952 | 19703 | 21470 | 21069 | 19927 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 1 | 1 | 1 | 1 | 1 |
| Additional Paid-In Capital | 4092 | 4271 | 4492 | 4661 | 4867 |
| Retained Earnings (Accumulated Deficit) | 14821 | 15392 | 16903 | 16324 | 14986 |
| Unrealized Gain (Loss) | 0 | -1 | -1 | -4 | -23 |
| Other Equity, Total | 38 | 40 | 75 | 87 | 96 |
| Total Liabilities & Shareholders’ Equity | 67492 | 67984 | 67098 | 67952 | 63080 |
| Total Common Shares Outstanding | 1254 | 1254 | 1255 | 1254 | 1255 |
- Anual
- Trimestral
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | 13488 | 4644 | 5460 | 5364 | 89 | 6201 |
| Efectivo de actividades de explotación | 17047 | 11898 | 8400 | 9144 | 8168 | 11384 |
| Efectivo de actividades de explotación | 177 | 233 | 226 | 255 | 288 | 329 |
| Amortization | 981 | 1053 | 1203 | 1149 | 1192 | 1721 |
| Deferred Taxes | -119 | -82 | 289 | -2098 | -214 | -116 |
| Partidas no monetarias | 974 | 942 | 2161 | 5272 | 8451 | 2760 |
| Cash Taxes Paid | 2436 | 3342 | 3198 | 1793 | 2639 | 2509 |
| Intereses pagados en efectivo | 885 | 1038 | 1070 | 982 | 951 | 979 |
| Cambios en el capital circulante | 1546 | 5108 | -939 | -798 | -1638 | 489 |
| Efectivo de actividades de inversión | -11985 | -16069 | 14355 | -7817 | -14615 | -3131 |
| Gastos de capital | -748 | -590 | -924 | -825 | -650 | -579 |
| Otras partidas de flujo de caja de inversión, total | -11237 | -15479 | 15279 | -6992 | -13965 | -2552 |
| Efectivo procedente de actividades de financiación | -9725 | 3393 | -12318 | -7634 | 770 | -8877 |
| Elementos de flujo de caja de financiación | -745 | -330 | -486 | -122 | -138 | -145 |
| Total Cash Dividends Paid | -2455 | -2731 | -2971 | -3222 | -3449 | -3605 |
| Emisión (retiro) de acciones, neto | -10793 | -720 | -2611 | -1540 | -1327 | -377 |
| Emisión (amortización) de deuda, neta | 4268 | 7174 | -6250 | -2750 | 5684 | -4750 |
| Efectos del cambio de divisas | 41 | 137 | -85 | -2 | 43 | -35 |
| Variación neta de la tesorería | -4622 | -641 | 10352 | -6309 | -5634 | -659 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1722 | 3239 | 5825 | 6201 | 12 |
| Cash From Operating Activities | 2610 | 4926 | 8179 | 11384 | 1840 |
| Cash From Operating Activities | 78 | 157 | 239 | 329 | 80 |
| Amortization | 395 | 835 | 1276 | 1721 | 445 |
| Deferred Taxes | 71 | 3 | 243 | -116 | -651 |
| Non-Cash Items | 753 | 1564 | 1921 | 2760 | 3116 |
| Changes in Working Capital | -409 | -872 | -1325 | 489 | -1162 |
| Cash From Investing Activities | -2042 | -2619 | -2853 | -3131 | -1070 |
| Capital Expenditures | -165 | -284 | -423 | -579 | -247 |
| Other Investing Cash Flow Items, Total | -1877 | -2335 | -2430 | -2552 | -823 |
| Cash From Financing Activities | -2477 | -3408 | -6935 | -8877 | -1794 |
| Financing Cash Flow Items | -89 | -95 | -134 | -145 | -91 |
| Total Cash Dividends Paid | -917 | -1811 | -2711 | -3605 | -945 |
| Issuance (Retirement) of Stock, Net | -221 | -252 | -340 | -377 | -258 |
| Issuance (Retirement) of Debt, Net | -1250 | -1250 | -3750 | -4750 | -500 |
| Foreign Exchange Effects | -23 | -3 | -26 | -35 | -18 |
| Net Change in Cash | -1932 | -1104 | -1635 | -659 | -1042 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.9329 | 111403199 | -68465 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.025 | 87609319 | 3078449 | 2022-12-31 | LOW |
| Capital World Investors | Investment Advisor | 5.5242 | 68892972 | 11130228 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.7263 | 58941373 | -298977 | 2022-12-31 | LOW |
| Capital Research Global Investors | Investment Advisor | 4.3784 | 54602952 | 727482 | 2022-12-31 | LOW |
| Dodge & Cox | Investment Advisor/Hedge Fund | 2.8775 | 35885152 | -484100 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.9123 | 23848477 | 244886 | 2022-12-31 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.3088 | 16322394 | 84245 | 2023-02-28 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.224 | 15265179 | 12533445 | 2022-12-31 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 1.1113 | 13859234 | 761084 | 2022-12-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0416 | 12989939 | -106202 | 2022-12-31 | LOW |
| Parnassus Investments, LLC | Investment Advisor | 0.9672 | 12062537 | 295282 | 2022-12-31 | LOW |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.8569 | 10686823 | -393685 | 2022-12-31 | LOW |
| BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.7805 | 9733453 | -126327 | 2022-12-31 | LOW |
| Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.7772 | 9693019 | -93438 | 2022-12-31 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7531 | 9391729 | -99918 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.7379 | 9202568 | -820000 | 2022-12-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7195 | 8972729 | -116113 | 2022-12-31 | LOW |
| California Public Employees' Retirement System | Pension Fund | 0.692 | 8630001 | -344541 | 2022-12-31 | LOW |
| Mellon Investments Corporation | Investment Advisor/Hedge Fund | 0.6788 | 8465274 | -377056 | 2022-12-31 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group 500000+
Traders
92000+
Clientes activos mensualmente
$53000000+
Volumen mensual de inversión
$30000000+
Pruébalo ahora Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Gilead Company profile
Sobre Gilead Sciences, Inc.
GILEAD SCIENCES, INC. es una compañía biofarmacéutica basada en la investigación que descubre, desarrolla y comercializa medicamentos en áreas de necesidad médica no cubierta. El portafolio de productos de la Compañía y su cartera de medicamentos en investigación incluye tratamientos para el Virus de la Inmunodeficiencia Humana / Síndrome de Inmunodeficiencia Adquirida (VIH / SIDA), enfermedades del hígado, cáncer, enfermedades inflamatorias y respiratorias y enfermedades cardiovasculares. Sus productos para pacientes con VIH / SIDA incluyen Descovy, Odefsey, Genvoya, Stribild, Complera / Eviplera, Truvada, Emtriva, Tybost y Vitekta. Sus productos para pacientes con enfermedades hepáticas incluyen Vemlidy, Epclusa, Harvoni, Sovaldi, Viread y Hepsera. Ofrece Zydelig a pacientes con enfermedades hematológicas / oncológicas. Sus productos para pacientes con diversas enfermedades cardiovasculares incluyen Letairis, Ranexa y Lexiscan. Sus productos para diversas inflamaciones / enfermedades respiratorias incluyen Cayston y Tamiflu. Tenía operaciones en más de 30 países, al 31 de diciembre de 2016.
- IndustriaBiotechnology / Medical Research
- Dirección333 LAKESIDE DR, FOSTER CITY, CA, United States (USA)
- Empleados14400
- CEODaniel O'Day
| Industry: | Pharmaceuticals (NEC) |
333 Lakeside Dr
FOSTER CITY
CALIFORNIA 94404-1147
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com